Yet, the second-generation TRK-inhibitors (repotrectinib) have shown efficacy against tumor cells with NTRK2 p.G639R substitution in preclinical studies37, but unfortunately did not have clinically relevant effect in this patient. Here, NTRK1 is linked to neoplasm.